GSK Set to Acquire Nuvalent in Multi-Product Oncology Deal
The deal centers on two FDA-reviewed NSCLC therapies with potential best-in-class profiles that will accelerate GSK’s expansion into lung cancer and support near-term growth alongside the company’s broader oncology strategy.
GSK has agreed to acquire Boston-based Nuvalent for USD 10.6 billion, strengthening its oncology pipeline and advancing its push into precision cancer medicines. The deal brings a portfolio of targeted therapies designed against clinically validated pathways, with a focus on overcoming resistance, improving tolerability, and addressing gaps in current standards of care (1).
The transaction focuses on two late-stage non-small cell lung cancer (NSCLC) therapies; zidesamtinib (NVL-520) and neladalkib (NVL-655). Both candidates, which have received breakthrough therapy and orphan drug designations, are under review by the FDA, with target action dates of Sep. 18, 2026 and Nov. 27, 2026 for zidesamtinib and neladalkib, respectively. Positioned as next-generation, highly selective kinase inhibitors, the therapies are designed to address key resistance mutations and improve outcomes for patients with ROS1- and ALK-driven disease.
Clinical data presented at the IASLC 2025 World Conference on Lung Cancer and the 2026 ASCO Annual Meeting indicate that both therapies may demonstrate best-in-class potential across multiple efficacy and safety parameters. The findings highlighted improved target selectivity, enhanced central nervous system penetration to address brain metastases, and more durable responses, alongside a favorable tolerability profile compared with existing treatments.
“[This] acquisition is a multi-product deal, consistent with our approach to acquire assets that have clinically proven targets and meaningfully address an efficacy and/or tolerability gap,” said Luke Miels, Chief Executive Officer, GSK, in a company press release about the acquisition (1). “The two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients with two forms of non-small cell lung cancer.”
Additionally, the acquisition incorporates a broader pipeline of earlier-stage and preclinical programs, led by NVL-330, a selective HER2-targeted candidate currently in Phase I development for HER2-altered NSCLC. Beyond its clinical assets, Nuvalent contributes a portfolio built on advanced structure-based drug design and deep translational expertise. The addition of these programs will provide GSK with both near-term pipeline depth and longer-term opportunities to develop differentiated targeted therapies across multiple tumor types.
Strategically, the acquisition accelerates GSK’s expansion into lung cancer, establishing a platform for growth in targeted therapies and enabling potential combination or sequencing approaches alongside its B7-H3 antibody-drug conjugate, Ris-Rez, currently in Phase III development. The addition of near-commercial and pipeline assets is expected to drive meaningful financial returns, with the company projecting contributions to sales and core operating profit from 2027.
Reference
GSK. GSK Enters Agreement to Acquire Nuvalent, Inc. Press Release, June 9, 2026.